CALT — Calliditas Therapeutics AB Share News
0.000.00%
Last trade - 00:00- $1.10bn
- $1.12bn
- SEK1.21bn
Brief: Calliditas: Supportive Interim Data From Phase 2 Head And Neck Cancer Trial With Lead NOX Inhibitor Candidate, Setanaxib
Brief: Calliditas Therapeutics Submits Supplemental New Drug Application To FDA
U.S. RESEARCH ROUNDUP-Magellan Midstream Partners LP, Onsemi, Viking Therapeutics
Brief: Calliditas Therapeutics Q1 Operating Loss At SEK 180.1 Mln
Brief: Calliditas Announces Primary Endpoint Successfully Met In Phase 3 Nefigard Trial Evaluating Nefecon In Iga Nephropathy
Brief: Calliditas Announces Primary Endpoint Successfully Met In Phase 3 Nefigard Trial Evaluating Nefecon® In IGA Nephropathy
Brief: Calliditas Announces Primary Endpoint Successfully Met In Phase 3 Nefigard Trial Evaluating Nefecon In IGA Nephropathy
Brief: Calliditas Therapeutics Q4 Revenues At SEK 429.0 Million
Travere Therapeutics soars as kidney disorder drug bags FDA approval
Travere Therapeutics rises as kidney disorder drug bags FDA approval
U.S. FDA approves Travere Therapeutics kidney disorder drug (updated)
U.S. FDA approves Travere Therapeutics' kidney disorder drug
Brief: Calliditas Therapeutics: China CDE/NMPA Recommends Priority Review for Nefecon
Brief: Calliditas Therapeutics, Viatris Enter License Agreement
Brief: Calliditas Partner Everest Medicine's Drug Application Accepted In China
Brief: Calliditas Therapeutics Q3 Oper Loss At SEK 36.2 Mln
U.S. STOCKS ON THE MOVE-Tesla, Xeris Biopharma
Brief: Calliditas Therapeutics Q2 Operating Loss Widens To SEK 209.8 Mln
Brief: Everest Medicines Announces European Commission Grants Approval Of Kinpeygo For Adults With Primary IgA Nephropathy To Our Partner Calliditas Therapeutics